| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMC070359 |
| P698 | PubMed publication ID | 17914053 |
| P2093 | author name string | Yi Guan | |
| Boping Zhou | |||
| Nanshan Zhong | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | convalescent plasma | Q105209484 |
| P304 | page(s) | 1450-1451 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Treatment with convalescent plasma for influenza A (H5N1) infection | |
| P478 | volume | 357 |
| Q96126008 | A current review of COVID-19 for the cardiovascular specialist |
| Q35099676 | A high-affinity CDR-grafted antibody against influenza A H5N1 viruses recognizes a conserved epitope of H5 hemagglutinin |
| Q30411637 | A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. |
| Q97422126 | A severe refractory COVID-19 patient responding to convalescent plasma; A case series |
| Q35779683 | A study in scarlet-convalescent plasma for severe influenza*. |
| Q36086664 | A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses |
| Q30384441 | Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. |
| Q30355446 | Adjunctive therapies and immunomodulating agents for severe influenza. |
| Q30429289 | Adjunctive therapies and immunomodulatory agents in the management of severe influenza |
| Q41495590 | An addition to treatment options for avian influenza A H5N1? |
| Q34046083 | An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses |
| Q96231151 | An overview on COVID-19: reality and expectation |
| Q90465416 | Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial |
| Q99240439 | Antibody response to SARS-Co-V-2, diagnostic and therapeutic implications |
| Q94533129 | Antibody-based therapies for COVID-19: Can Europe move faster? |
| Q40156032 | Antibody-dependent NK cell degranulation as a marker for assessing antibody-dependent cytotoxicity against pandemic 2009 influenza A(H1N1) infection in human plasma and influenza-vaccinated transchromosomic bovine intravenous immunoglobulin therapy |
| Q30376292 | Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets |
| Q30366719 | Antiviral combinations for severe influenza. |
| Q37298680 | Antiviral therapy for respiratory tract infections |
| Q30393095 | Antivirals for influenza: strategies for use in pediatrics |
| Q37087632 | Avian influenza A (H5N1) infection in a patient in China, 2006. |
| Q38708817 | Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens |
| Q45383054 | Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors |
| Q57051585 | Case Report: Use of Plasma Exchange Followed by Convalescent Plasma Therapy in a Critically Ill Patient with Severe Fever and Thrombocytopenia Syndrome-Associated Encephalopathy: Cytokine/Chemokine Concentrations, Viral Loads, and Antibody Responses |
| Q33361942 | Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China |
| Q30383661 | Clinical management of pandemic 2009 influenza A(H1N1) infection. |
| Q30377663 | Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. |
| Q33328393 | Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies |
| Q42199554 | Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice |
| Q36392511 | Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection |
| Q33973410 | Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast |
| Q37704596 | Construction of a chimeric secretory IgA and its neutralization activity against avian influenza virus H5N1. |
| Q57093891 | Contemporary management of severe influenza disease in the intensive care unit |
| Q91849630 | Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying |
| Q94488415 | Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic |
| Q30398715 | Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. |
| Q95300819 | Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases |
| Q26775412 | Convalescent plasma: new evidence for an old therapeutic tool? |
| Q30385673 | Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? |
| Q95602418 | Coronaviruses pandemics: Can neutralizing antibodies help? |
| Q37141589 | Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir |
| Q30392802 | Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations |
| Q24656164 | Current and future antiviral therapy of severe seasonal and avian influenza |
| Q92879909 | Current and novel approaches in influenza management |
| Q96607521 | Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies |
| Q30369241 | Ebola virus convalescent blood products: where we are now and where we may need to go. |
| Q91611037 | Effectiveness of convalescent plasma therapy in severe COVID-19 patients |
| Q97093644 | Effects of the COVID-19 pandemic on supply and use of blood for transfusion |
| Q104105897 | Emergence of Ancient Convalescent plasma (CP) Therapy: to Manage COVID-19 Pandemic |
| Q33350700 | Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. |
| Q55554478 | Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy. |
| Q30376814 | Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. |
| Q30401524 | Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus |
| Q21562507 | Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells |
| Q44925086 | High yield of human monoclonal antibody produced by stably transfected Drosophila schneider 2 cells in perfusion culture using wave bioreactor. |
| Q34894660 | How to approach and treat viral infections in ICU patients |
| Q34721639 | Human monoclonal ScFv that bind to different functional domains of M2 and inhibit H5N1 influenza virus replication |
| Q37026347 | Human monoclonal antibodies by immortalization of memory B cells |
| Q96647310 | Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art |
| Q30379199 | INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. |
| Q33795341 | Iminosugars: Promising therapeutics for influenza infection |
| Q99558038 | Immune responses during COVID-19 infection |
| Q97561560 | Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro |
| Q50064174 | Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017. |
| Q90486818 | Influenza Infections and Emergent Viral Infections in Intensive Care Unit |
| Q30354157 | Influenza and endemic viral pneumonia. |
| Q30391974 | Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice |
| Q30401056 | Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection. |
| Q30385394 | Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic |
| Q30364385 | Mammalian models for the study of H7 virus pathogenesis and transmission. |
| Q33432749 | Mapping antibody epitopes of the avian H5N1 influenza virus |
| Q96225925 | Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy |
| Q30359683 | Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis. |
| Q30372987 | Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. |
| Q98158924 | Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment |
| Q30429431 | New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain |
| Q30456363 | Newer influenza antivirals, biotherapeutics and combinations |
| Q30416784 | Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem |
| Q30412025 | Pandemic H1N1 influenza |
| Q30367936 | Passive broad-spectrum influenza immunoprophylaxis |
| Q30413158 | Passive immune neutralization strategies for prevention and control of influenza A infections |
| Q57020908 | Pathogenesis of pandemic H1N1 2009 influenza virus infection and the implication on management |
| Q55263258 | Patient-derived avian influenza A (H5N6) virus is highly pathogenic in mice but can be effectively treated by anti-influenza polyclonal antibodies. |
| Q99633101 | Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study |
| Q38699406 | Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. |
| Q40134490 | Position on blood collection and use of convalescent plasma as a treatment option in the outbreak of severe infections |
| Q97438796 | Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy |
| Q36829831 | Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China |
| Q30401260 | Preventing and treating secondary bacterial infections with antiviral agents |
| Q43175708 | Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China |
| Q34737817 | Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses |
| Q35989939 | Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus |
| Q34990306 | Prophylaxis and therapy for Chikungunya virus infection |
| Q27324824 | Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection |
| Q30222441 | Rapid Generation of Human-Like Neutralizing Monoclonal Antibodies in Urgent Preparedness for Influenza Pandemics and Virulent Infectious Diseases |
| Q57930420 | Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies |
| Q46139825 | Report of the 'mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, USA. |
| Q35158123 | Rural villagers and urban residents exposure to poultry in China |
| Q98944371 | SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma |
| Q30378572 | Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. |
| Q41495598 | Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study |
| Q40170219 | Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China |
| Q64130617 | Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1 |
| Q35909991 | Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody |
| Q30399477 | Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus |
| Q39319893 | Tackling influenza with broadly neutralizing antibodies |
| Q99237794 | The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19 |
| Q35974433 | The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States |
| Q30365366 | The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. |
| Q90296531 | The convalescent sera option for containing COVID-19 |
| Q27001157 | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis |
| Q42250194 | The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities |
| Q34291530 | The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus |
| Q37027166 | The growth and potential of human antiviral monoclonal antibody therapeutics. |
| Q47554935 | The role of adjuvant immunomodulatory agents for treatment of severe influenza |
| Q37975932 | Therapeutics against influenza |
| Q96024297 | Treatment algorithm for COVID-19: a multidisciplinary point of view |
| Q90702138 | Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma |
| Q30224656 | Two years after pandemic influenza A/2009/H1N1: what have we learned? |
| Q30375991 | Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. |
| Q42559493 | Use of Plasma Therapy for Severe Fever with Thrombocytopenia Syndrome Encephalopathy |
| Q41667356 | Use of intravenous immunoglobulin in critically ill patients |
| Q99419033 | What are the drugs having potential against COVID-19? |
| Q28475630 | What is the optimal therapy for patients with H5N1 influenza? |
Search more.